CURRICULUM VITAE:

Pragya B. Gupta MD, DABPM, FRCS (Edin).
ABA Subspecialty Certification in Pain Medicine
Fellow of the Academy of Physician in Clinical Research
Certified Principal Investigator- ACRP
Diplomate of American Board of Anesthesiology
Diplomate of American Board of Pain Medicine
Fellow of the Royal College of Surgeons of Edinburgh

Home Address:
3466 Reeves Drive,
Edgewood, KY 41017
Office Address:
162 Barnwood Drive
Edgewood, KY 41017
Tel: (859) 468 2563 – Cell
pbgupta@aptcmd.com
pbgupta222@uky.edu

Current Position:
Director & Owner
Feb 22, 2002 - Advanced Pain Treatment Center, 162 Barnwood Drive, Edgewood, KY 41017. Tel: (859) 331 4159 www.aptcmd.com
Nov 2012- Otrimed Clinical Research, 162 Barnwood Drive, Edgewood, KY 41017.
Tel: (859) 7571359 www.otrimedresearchcenter.com
Academic Appointment:
2001 July: Assistant Professor, Department of Anesthesiology and Pain Medicine, Volunteer, AHEC Faculty. ID 10840536. Appointment until 2022.
University of Kentucky Medical Center, Lexington, KY 40536.

Past Position:
Member, Evidence Analysis Committee: Spine Intervention Society 2015 – 2017, July

Education and Qualification:
2016: Certified Principal Investigator (9/2016), Academy of Clinical Research Professionals – ACRP – active (recertified-2018).
2016: Fellow of the Academy of Physicians in Clinical Research- APCR.
2011: Diplomate of American Board of Pain Medicine (recertification, first certified in 2001, # 08901)
2021: ABA Subspecialty certification in Pain Medicine (recertification, first certified in 2000 & 2010 # 32482, ABAID: 3581-7303). 60 CME AMA 1 category.
1999: Diplomate American Board of Anesthesiology (Indefinite expiry, ABAID: 3581-7303).
1994: Fellow of the Royal College of Surgeons of Edinburgh by exam (General surgery); United Kingdom.
1985: Bachelor of Medicine and Bachelor of Surgery, Calcutta University, R.G. Kar Medical College, India.
07/2015: Appraisal of Evidence in Studies of Diagnostic Tests and Strategies, Evidence Based Medicine Part 1 & 2. Spine Intervention Society, Educational Program.

Past Employments:

July 1999 – 2000: Director Pain Control Center, Clark Regional Medical Center, Winchester, KY 40391 Jan 21, 2001 – Feb 21, 2002: Medical Director, Ohio Valley Chronic Pain Center, US Highway 42W – S Warsaw, KY 41095

Hospital Affiliations:
Jan 19, 2001 – St. Elizabeth Medical Center, Medical Village Drive, Edgewood, KY 41017 (full admitting privileges)
Jan 1, 2019 - The Christ Hospital Network, Cincinnati OH

Licensure:

1. Kentucky Board of Medical Licensure # 34***, date issued 6/17/1999 - active
2. Commonwealth of Massachusetts # 1****, date issued 12/10/1997 - active
3. Medical Board of Ohio, # 35-08-****, date issued 02/14/2003 – active
4. Medical Board of California, # C15****, date issued 10/04/2017 - active
5. General Medical Council, United Kingdom Registration # 4064804 1993
6. Indian Medical Council registration #43916 - 1985

National Provider Identity Number (NPI) # 174024xxxx
DEA (KY): BG 5753xxx, XG5753xxx
ECFMG # xxx-166-5
CITIZEN: USA

GCP CERTIFICATION 16 Nov 2020 – 16 Nov 2022 (CITI – Copernicus group IRB);
GCP for Clinical Trials with Investigational Drugs and Medical Devices - U.S. FDA – CME 6 Category 1 Focus (Albert Einstein College of Medicine)
GCP Training: Nov 1, 2019 : Clinical Research Training for Physicians, sponsored by Encore Research Group (TransCelerate BioPharma, Inc).

AWARD NOTIFICATION: Dr. Gupta and team of Otrimed Corporation is a Recipient of the 2018 Syneos Health Site Appreciation Award

Clinical Research - Principal Investigator:

Opioid Induced Constipation:

1. A safety and efficacy evaluation of BLI801 Laxative in Adults Experiencing Non-Idiopathic constipation.
2. A phase 3 randomized, double blind, placebo controlled, parallel group study of NALDEMEDINE in the treatment of opioid-induced constipation in subjects with nonmalignant chronic pain receiving opioid therapy.
3. A phase 3 randomized, double-blind, double dummy, placebo controlled, active controlled, parallel group, multicenter trial of oxycodone/ naloxone controlled release tablet (OXN) to assess the analgesic efficacy (compared to placebo) and the management of opioid-induced constipation (compared to oxycodone controlled release tablets (OXY) in opioid experienced subjects with uncontrolled moderate to severe chronic low back pain and a history of opioid- induced constipation who required around-the-clock opioid therapy.

Sciatica Study:

4. A phase 2A, open, sequential, dose escalation study of the pharmacokinetics, safety and preliminary efficacy of MDT – 15 in subject with lumbosacral radiculopathy.
5. A Prospective Multicenter Randomized Double-Blind Sham Controlled study to evaluate the efficacy and safety of Clonidine Micro pellets for the treatment of pain associated with lumbosacral radiculopathy in Adults
6. A Multicenter, Randomized, Double-blind, Sham-controlled, Comparative Study of SI-6603 in Subjects with Lumbar Disc Herniation (Phase 3).

LOW BACK PAIN – Degenerative Disc Disease- (STEM CELL CLINICAL TRIALS):

7. A phase 3 prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single injection of **Rexlemastrocel-L** alone or combined with hyaluronic acid in subjects with chronic **discogenic lumbar back pain** through 12 months.

8. Phase I, first in human, randomized, double-blind, vehicle and placebo-controlled, parallel group, multi-center study in subjects with single level, symptomatic lumbar intervertebral disc degeneration (>6 months) and unresponsive to conservative therapy for at least 3 months. The study will compare single intradiscal injections of high and low dose IDCT with two control groups (saline, Sodium Hyaluronate).

9. A prospective, randomized, double blinded, vehicle- and placebo-controled, multicenter study to evaluate this safety and preliminary efficacy of IDCT in subjects with single-level, symptomatic lumbar intervertebral disc degeneration.

LOW BACK PAIN – Degenerative Disc Disease / Non Specific Low back pain

10. A phase 3 randomized, double-blind, placebo and active controlled multicenter, parallel group study of the analgesic efficacy and safety of subcutaneous administration of **Tanezumab** in the adult subjects with chronic low back pain.
11. A phase 3 randomized, double-blind, double dummy, placebo controlled, active controlled, parallel group, multicenter trial of oxycodone/ naloxone controlled release tablet (OXN) to assess the analgesic efficacy (compared to placebo) and the management of opioid-induced constipation (compared to oxycodone controlled release tablets (OXY) in opioid experienced subjects with uncontrolled moderate to **severe chronic low back pain** and a history of opioid- induced constipation who required around-the-clock opioid therapy.
12. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Enriched-Enrollment Withdrawal, Multicenter Study to Evaluate the Efficacy and Safety of a Long-Acting Subcutaneous Injectable Depot of **Buprenorphine (CAM2038)** in Subjects with Moderate to Severe Chronic Low Back Pain Currently Treated with Daily Opioid.
13. A phase 3, Randomized, Double blind, Placebo controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Moderate to Severe Chronic Low back pain and Osteoarthritis of Hip or Knee (Study was put on hold in (2018 March).

IMPLANTABLE SPINAL CORD STIMULATION TRIAL:

14. Medtronic products surveillance registry version 6 (PSR-V6). The purpose of the PSR platform is to provide continuing evaluation and periodic reporting of the safety and effectiveness of market released products for their intended use. Products surveillance is the systematic

collection, analysis, and interpretation of performance data as well as its dissemination and application. Phase 4 study (Chronic Neuropathic pain).

Post Traumatic Neuropathic Pain

15. A phase 3 randomized double-blind placebo controlled parallel group study of the efficacy and safety of pregabalin (twice a day) in subject with posttraumatic peripheral neuropathic pain.
16. SPRINT peripheral nerve stimulation for the treatment of Neuropathic post-Amputation Pain in a randomized, double-blinded, placebo-controlled, multicenter trial.

Migraine Study:

17. A phase IIb Randomized, double-blind, placebo-controlled study of LY2951742 in patients with episodic migraine.
18. A phase 3, randomized, double-blind, and placebo-controlled study of LY2951742. Patient with episodic migraine.
19. A phase 3, randomized double-blind, parallel group, multicenter placebo-controlled dose ranging study to evaluate the efficacy and safety of AMG 334 in migraine prevention.
20. A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of multiple dosing regimens of oral **ATOGEPANT** for the prevention of migraine in patients with episodic migraine.
21. 15Q-MC-BOO4/2016-4215 Observational Study Protocol: Protocol 15Q-MC-B004: Preventive TReatment of mIgraine oUtcoMes for Patients in real-world Healthcare systems (TRIUMPH). GPORWE-2016-4215.

Diabetes Mellitus:

22. A phase 3, randomized, 16 weeks, multiphase, double-blind, placebo controlled dose ranging study to evaluate glycemic effect, safety and tolerability of metformin delayed release in subjects with type II diabetes mellitus

Osteoarthritis Joint Pain- Degenerative Joint Disease

23. A phase 3, randomized, 16 weeks, multi-phase, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of Fulranumab as a monotherapy in subjects with signs and symptoms of osteoarthritis of the hip or knee. A phase 3 randomized, double-blind, placebo and active controlled multicenter, parallel group study of the analgesic efficacy and safety of subcutaneous administration of **Tanezumab** in the adult subjects with chronic low back pain.
24. A phase 3 randomized, double-blind, double dummy, placebo controlled, active controlled, parallel group, multicenter trial of oxycodone/ naloxone controlled release tablet (OXN) to assess the analgesic efficacy (compared to placebo) and the management of opioid-induced constipation (compared to oxycodone controlled release tablets (OXY) in opioid experienced subjects with uncontrolled moderate to **severe chronic low back pain** and a history of opioid- induced constipation who required around-the-clock opioid therapy.

Opioid Dependence

25. Induction, Stabilization, adherence and Retention Trial (ISTART)- a randomized non-inferiority

multicenter study to assess early treatment efficacy of OX219 (combination of **Buprenorphine** and Naloxone) and **Suboxone** and to explore switching between treatments. Phase 3 Study.

26. A randomized, double blind, placebo-controlled pilot study to evaluate the safety and effectiveness of lucemyra in the treatment of opoid withdrawal during an opioid taper in subjects with chronic non-cancer pain.

Depression:

27. ALK5461-208, A phase 3 multicenter study of the long-term safety and tolerability of ALKS 5461 for the adjunctive treatment of major depressive disorder in adults who have been inadequate response to antidepressant therapy (the FORWARD-2 Study).
28. ALK5461-208, A phase 3 multicenter study of the long-term safety and tolerability of ALKS 5461 for the adjunctive treatment of major depressive disorder in adults who have been inadequate response to antidepressant therapy (the FORWARD-3 Study).
29. The SPD 489-322 A phase 3, multicenter, randomized, double-blind, parallel group, placebo-controlled, flexible dose titration, efficacy and safety study of SPD 489 incombination with an antidepressant in the treatment of adults with major depressive disorder with inadequate response to prospective treatment with an antidepressant (Sub-Investigator).
30. The SPD489-322 A phase 3, open label, multicenter, 12-month extension safety and tolerability study of SPD 489 in combination with an antidepressant in the treatment of adults with major depressive disorder with residual symptoms of inadequate response following treatment with an anti-depressant (SI).
31. A Phase II a double blind, placebo controlled multicenter study of Sirukumab as adjunctive treatment to a monoaminergic antidepressant in adult with Major Depressive Disorder (SI).
32. A multicenter, randomized double-blind, parallel-group, placebo-controlled studies evaluation the efficacy, safety, and pharmacokinetics of SAGE-547 injection in the treatment of adult female subjects with severe postpartum depression and adult female subjects with moderate postpartum depression. 547-PPD-202.
33. A multicenter, double blind, placebo-controlled study evaluation the efficacy, safety, tolerability, and pharmacokinetics of Brexanolone in the treatment of **adolescent f**emale subjects with postpartum depression. Protocol Number: 547-PPD-304.

POST TRAUMATIC STRESS DISORDER:

34. A phase 3, Multicenter, Randomized, Double-blind Trial of Fixed-Dose Brexpiprazole as Combination Therapy with Sertraline in the Treatment of Adults with Post-traumatic Stress Disorder.

MUSCLE SPASM:

35. Double blind, randomized, placebo-controlled, multiple -dose parallel group study of the efficacy and safety of multiple doses of tolperisone administered as multiple doses three times daily in 400 male and female

Publication:

- Spontaneous Rupture of Spleen Secondary to Metastatic Carcinoma. PB Gupta & LHarvey, British Journal of Surgery. Vol 80, May 1993, 613

- Book Review: Sickle Cell Pain by Samir Ballas, IASP Press Seattle. PBGupta, DBCarr; Acute Pain (International Journal of Acute Pain Management). Volume 1 (5) Dec.1998.

Interventional Pain Procedures routinely performed in Private Medical Practice:

- Balloon Kyphoplasty
- Provocation Diagnostic pressure controlled Discogram
- Intradiscal therapies (PRP, Stem Cells implantation- currently implanting stem cells as a part of an industry sponsored clinical trial)
- PRP treatment for Tendinitis, tendon tear or rupture, joint pain etc.
- Spinal Cord Stimulation with implantation of Generator
- Intrathecal Drug Delivery using Implantable pump, epidural infusion using external programmable pump.
- **Ultrasound guided procedures** such as Stellate Ganglion block, Serratus Anterior Plane block, Major joint injections, Interscalene blocks, paravertebral blocks, thoracic and cervical facet joint blocks etc, Adductor canal block, Shoulder joint (suprascapular and axiallary nerve) and Knee joint blocks.
- Radiofrequency Neurotomy of Cervical and Lumbar Z joints and Thoracic Z joints where possible.
- Cooled RF lesioning of Genicular nerves for Knee joint pain (post arthroplasty chronic pain), SI joint pain and Lumbar Z joint pain.
- Fluoroscopy guided diagnostic and therapeutic Cervical, Thoracic and lumbar TF injections, medial branch blocks, joint injections, Caudal epidural Neuroplasty, LSPB, Pelvic Plexus blocks, Splanchnic nerve block, Celiac plexus block, Ganglion Impar block etc.

Research Interest:

- Regenerative Medicine and its role in treating chronic discogenic low back pain, OA (post traumatic and secondary OA), tendinitis and other soft tissue related pain.
- Neuroaugmentation treatment in neuropathic painful conditions
- Peripheral nerve stimulation for treating neuropathic pain.
- Cervicogenic headache and Migraine Headache

ACGME - Post Graduate Training in the USA:

1. July 1998 – June 1999: Fellowship – Pain Medicine. Tufts Medical Center (Previously New England Medical Center), 750 Washington Street, Boston MA 02111
2. July 1995 – June 1998: Residency/ Senior Resident – Anesthesiology, Tuft Medical Center (Previously New England Medical Center), 750 Washington Street, Boston, MA 02111
3. July 1994 – June 1995: Internship – General Surgery, University of Illinois – Metro Group of Hospital General Surgery Program. Illinois Masonic Medical Center, 836 W Wellington Avenue, Chicago, IL 60657-5193.

Hands on Cadaver Spine Intervention Courses and Training:

- May 31, 2014: Cooled RF lesioning procedures for chronic pain management. Intervertebral disc Biacuplasty, cervical, thoracic and Lumbar Z joints, Sacro-iliac joint and peripheral denervation (genicular, obturator and femoral articular branches). Barrow Neurological Institute, St. Joseph's Hospital and medical center, 350 W Thomas Road, Phoenix, Arizona 85013.
- April 26, 2014: PRP Autologous Stem Cell Therapy course. Use of BMAC/PRP for treatment of Soft tissue disease, Park City, Utah. Non-CME
- November 23, 2013: Spine Endoscopy Workshop (Endoscopic discectomy and endoscopic dorsal ramus neurectomy or rhizotomy), Richard Wolf Didactic instruction and hands on training.
- March 16, 2013: **Kyphon Balloon Kyphoplasty** Physician Training, Memphis TN
- February 13, 2013: Percutaneous Discectomy course, Elliquence, New York, NY

- June 2011: Intrathecal Drug Delivery device training, Medtronic, Chicago, IL
- April 30, 2011: Vertebral Augmentation Course/ **Kyphoplasty**, Stryker, Atlanta, GA.
- September 2008: SCS implantation techniques Advanced Bionics, NYU ALBERT Einstein Medical Center, NYC, NY
- March 24, 2007: SCS implant techniques, Advanced Bionics, Baltimore, MD
- January 2007: Vertebral Augmentation Course/ **Kyphoplasty**, Stryker, University of Cincinnati, OH.
- February 24 – 25, 2006 4th European Course on Minimally Invasive Spine Surgery, Monastier di Treviso, Park Hotel, Villafiorita, Italy.
- November 2001: Phase 5 Spine Intervention Society course (SIS), RF neurotomy and Intradiscal Electro Thermal Coagulation, Percutaneous disc decompression cadaver workshop, Austin, TX CME: 13 hours Category 1.
- October 2001: Spine Intervention Society (SIS) Discography workshop using Cadavers, CME 13 hours (Category 1). MERI, Memphis, TN.
- June 2001: Minimally Invasive Surgical Strategies, Cadaver workshop; IDET, Discography, and **Vertebroplasty** – Wilmington, MA, 16 Hours Category 1 CME.
- March 2001: Phase 3, Cervical spine injection workshop using Cadaver; Chicago, IL Spine Intervention Society (SIS) CME – 1, 13 Hours.
- Sept 2000: Interactive Surgical Training Skills Lab (Cadaver course), Maricopa Integrated Health System, Wilmington, MA. CME: Category 1, 15 hours.
- August 2000: Advanced Lumbar and Thoracic workshop (Cadaver)- Spine Intervention Society (SIS); Memphis, TN. CME -1: 13 Hours.
- Dec 1999: Interventional Pain Management Technique (Cadaver Course), Dallas, TX.

Advanced Cardiac Life Support Provider Course:

- October 1993: Advanced Trauma Life Support Course, Oxford University, Oxford, United Kingdom.
- 2002: St. Luke Hospital, Florence, KY CME: 2 hours
- 2002: Neonatal Resuscitation Program (NRP), The Christ Hospital, Cincinnati, OH.
- 2004: St. Luke Hospital, Ft. Thomas, KY CME: 2 hours
- 2006: St. Luke Hospital, Ft. Thomas, KY CME: 2 hours
- 2008: Christ Hospital, Cincinnati, OH, CME: 2 hours

- 2010: Christ Hospital, Cincinnati, OH, CME: 5 hours
- 2012: St. Elizabeth Medical Center, North Unit, Covington, KY. CME 5 hours
- 2014: Northern Kentucky Emergency Medical Service, KY 41075, CME: 2 hours
- 2015: University Hospital, OH 03258, Cincinnati OH 45219. CME 5 hours
- 2016: Northern Kentucky Emergency Medical Service, KY 41075, CME: 2 hours.
- 2018: United Medical Education CME: 4 Hours Cat 1.
- 2020: United Medical Education *ACLS Provider Manual Recertification Credit* CME: 4 Category 1.

HIV & AIDS updates:

- March 10, 2003: HIV/AIDS update 2001 – Twenty years of HIV in the US marking a milestone. KY CHS course # 1103-1528-M Course Department of Pharmacy UKMC.
- August 12, 2012: HIV certification for Medical Providers at CE Central, Lexington, KY

Office based Treatment of Opioid use disorder (Buprenorphine / Suboxone) certification Courses:

- October 5, 2008: Suboxone prescribing Certification course (SAMHSA accredited), Lexington, KY. CME-1: 8 Hours.
- October 15, 2017: Office Based Treatment of Opioid Dependence, American Academy of Addiction Psychiatry Certification. 8 AMA PRA Category 1 Credits
- **November 22, 2020: 8 hour** online MAT Waiver Course, American Academy of Addiction Psychiatry. 8 hours of CME AMA-1
- Nov 2020: Psychiatric Comorbidities: Diagnosis and Treatment of Comorbid Psychaitric Disorders and Opioid Use disorders – Revised; 1.50 CME AMA Catetory 1.
- Nov 2020: Medication for Opioid Use Disorder; American Academy of Addiction Psychiatry; CME 1.5, AMA 1
- Nov 2020: Methadone and Buprenorphine Associated Drug – Drug interactions; American Academy of Addcition Psychiatry; CME 1, AMA Category 1.

Opioid and HB 1 MANDATED Courses:

- August 22, 2010: Responsible Opioid Prescribing: A physician' guide. University of Wisconsin School of Medicine. CME-1: 7.25 hours.
- June 10 – 12, 2012: International Conference on Opioid, Harvard Medical School, Boston, MA. CME-1, 16 hours.
- September 28, 2014: Scope of Pain; Safe and competent Opioid Prescribing Education. Category 1: 3 hours, Boston University.
- September 9, 10 2017, Opioid Prescribing and Addiction, 5 CME - AMA PRA Category 1. The University of Kentucky College of Medicine, Lexington, KY
- Sept 9, 2017: Heroin: An old Dog with new tricks CME 1, category.
- Sept 10, 2017: Substance Abuse Treatment as an integral part of the health care system: CME 1, Category1
- Treating women with opioid use disorders: A focus on Pregnant and parenting women, CME 1 Category 1
- Therapeutic uses of KASPER and Urine Drug Testing in clinical Practice, CME: 0.75, Category 1
- Responding to the prescription opioid and heroin crisis, An Epidemic of Addiction, CME: 1.25, category 1.

- August 7, 2018 Louisville, KY; Practioner's Diversion Awareness Conference; Organized by KMBL & DEA.
- April 15, 2019: Scope of Pain: Safer/ Competent Opioid Prescribing Education. Boston University School of Medicine. CME category 1 – 2.
- April 28, 2019: A patient-centered approach to opioid tapering , BU school of Medicine, 0.5 CME 1.
- 7/29/2019: Evidence-Based Guidance on Responsible Prescribing, Effective Management, and Harm
  Reduction, CDC Opioid Prescribing Guidelines for Chronic Pain, Prescriber Education for Opioid Analgesics, End-of-Life: Domains and Communication on **and is awarded 12.0 AMA, Category 1.**
- 11/22/2020: Harm Reduction and the opioid Syndemic. 0.5 AMA 1, CE central, UKMC
- 11/22/2020: Podcast 2: Creating a Pain Treatment Plan 0.5 AMA 1 , CE Central UKMC
- 11/22/2020: Tips for Prescribing / Dispensing Controlled Substances within the Law, 0.5 AMA 1, CE Central UKMC
- 11/22/2020: Gabapentine: Possible Misues Leads to Scheduling in Kentucky, 0.75 AMA 1, CE Central KY
- 11/22/2020: Substance Use Disorders in Your Medical Practice: Treatment and Referral Update: 1 AMA 1, CE Central UKMC
- 11/21/2020: Drug Conviction Data in KASPER: What is prescriber to do? 1.50 AMA 1, CE Central UKMC.
- 11/23/2020: Clinical Considerations of Substance Abuse and Critical Components of Proper Prescribing Series-Session One. CME 1, Category 1 Kentucky Medical Association
- 11/23/2020: Clinical Considerations of Substance Abuse and Critical Components of Proper Prescribing Series-Session Two. CME 1, Category 1 Kentucky Medical Association

Risk Management Courses:

- October 2007: Risk management, Failure to diagnose, Medical Protective sponsored, Cincinnati, OH. CME-1: 8.5 hours
- April 21, 2010 & July 22, 2010: Risk Management course. Repairing difficult Patient Relationships. Medical Protective sponsored. CME -1, 8.5 hours, Cincinnati OH.
- October 23, 2014: Risk Management Course. Disclosure of Medical Errors, Medical Protective sponsored. CME 7.5 hours. Cincinnati, OH.
- Nov 5 2018; Risk Management Consult: Managing Disruptive Physician Behavior; CME 5 Category 1 AMA
- 2018: Risk Management Consult: Pain Management 2nd edition; CME 6 Category 1 AMA.
- 2019: 12/15/2019 Basic Training on the Safe Use of Fluoroscopy. Approved for 1.8 Category 1 Risk management CME credits.
- November 24, 2020; Risk Management Focus: Pain Management – Medical Risk Management. CME – 1 Category 1.
- November 24, 2020: Risk Management Focus: Electronic Medicine – Medical Risk Management CME – 5, Category 1.

Sexual and Domestic Violence:

- **Training and education in sexual and domestic violence compliance with Chapter 260, Sept 10, 2020 Commonwealth of Massachusetts department of health.**

Pain Medicine Ultrasonography Training:

- August 17 – 18, 2013: World Academy of Pain Medicine Ultrasonography (previously AAPMU); Level 2, advanced ultrasound techniques in pain medicine, (16 category 1 CME), Phoenix Arizona.
- March 9 – 10, 2013; World Academy of Pain Medicine Ultrasonography (previously AAPMU); Level 3, 16 hours CME-category 1) Henderson, Nevada.
- March Feb 9, 2013; World Academy of Pain Medicine Ultrasonography (previously AAPMU); Level 1, 8 hours CME-category 1) Henderson, Nevada.
- October 2015; World Academy of Pain Medicine Ultrasonography (previously AAPMU); Level 2, 16 hours CME-category 1, Chicago, IL.
- Nov 18, 2019: Masterclass Training workshop on Percutaneous Peripheral Nerve Stimulation Implants. – SPRINT SPR Therapeutics, PNS system. New Orleans, LA.

Certification in EMG and NCS:

- August 22 – 23 2015: Attended TeleEMG workshop on Nerve Conduction Studies.

X – Ray and Fluoroscopy:

- Dec 15, 2019: Basic Training on the Safe Use of Fluoroscopy: Course # E2019-3, CME 1 – 4 hours , FluoroSafety Certification
- March 1, 2006: Mercy Health Partner, Mercy Hospital, Fairfield, OH. Minimizing Risks from Fluoroscopic X Ray: Bioeffects, Instrumentation and Examination.
- Sept 28, 2001: St. Elizabeth Medical Center, Edgewood, KY 41017. Completion of Fluoroscopy

Annual Scientific Clinical Research Conferences:

- 2013 Dec 6 – 7, Clinical Research and GCP training & Certification, Academy of Physician in Clinical Research, University of North Florida, Encore Research Group, Jacksonville, FL. CME-1:
  12.75 hours.
- 2016 November 6 -7, 15th Annual Clinical Research and GCP Training & certification for Physician, Academy of Physician in Clinical Research, Encore Research Group, University of North Florida, Jacksonville, FL. CME-1: 12.25 hours.
- Pain and Migraine Therapeutics Summit, Sept 27 – 28 2017, San Diego, CA.
- Pain and Migraine Therapeutic Summit, October 10 – 11, 2018, San Francisco, CA.
- 2018 November 6 -7, 15th Annual Clinical Research and GCP Training & certification for Physician, Academy of Physician in Clinical Research, Encore Research Group, University of North Florida, Jacksonville, FL. CME-1: 12.25 hours
- Nov 13-15, 2018: FDA Clinical Investigator Training Course Nov 13 - 15, 2018. CME: 19 Hours Category 1
- Nov 1 -2, 2019 APCR Annual Meeting 2019, Orlando FL, CME: 15.75hours Category 1

Annual Scientific Meeting and Conferences:

- 2003 11th Spine Intervention Society, Orlando FL, CME-1: 17 hours
- 2003 Annual Meeting American Academy of Pain Medicine, Orlando, FL CME-1: 42 hours
- 2004 12th Spine Intervention Society, Maui, Hawaii, CME -1, 17 hours
- 2005 International Intradiscal Therapy Society, San Diego, CA. CME-1: 15 hours
- 2006 14th Spine Intervention Society, Salt Lake City, UT. CME-1: 17 hours
- 2006 Dec 7 – 10, North American Neuromodulation Society, Las Vegas, NV. CME-1: 18 Hours
- 2007 July 18 -22, 15th Spine Intervention Society, Baltimore. CME-1: 18 hours
- 2008 July 23 – 26, 16th Spine Intervention Society, Las Vegas, NV. CME-1: 27 Hours
- 2009 July 23 – 25, 17th Spine Intervention Society, Toronto, Canada. CME-1: 25.4 hours
- 2010 July 13 – 17, 18th Spine Intervention Society, Grand Wailea, Maui, HI. CME-1: 23 hours
- 2011 March 24-27, American Academy of Pain Medicine, Washington, DC. CME-1: 16 hours
- 2011 August 10 -13, 19th Spine Intervention Society, Chicago, IL. CME-1: 18.75 hours.
- 2013 July 16 – 20, 21st Spine Intervention Society, New York City, NY. CME-1: 19 hours.
- 2013 Dec 8, North American Neuromodulation Society, Las Vegas, NV. CME-1: 4 hours
- 2014 July 28 – Aug 3, 22nd Spine Intervention Society & Evidence Based Medicine, Orlando, FL I. CME-1: 28 hours.
- 2015 July 28 – August 1, 23rd Spine Intervention Society & Evidence Based Medicine II, Las Vegas, NV. CME-1: 27 hours.
- 2016 July 28 – 30, 24th Spine Intervention Society, New Orleans, LA, CME-1: 18.75 hours.
- 2017 July 19 – 22, 25th Spine Intervention Society, San Francisco, CA, CME-1: 18.75 hours.
- 2018 August 15 – 18, 2018 26th Spine intervention Society, Chicago, CME 18.5 hours.
- 2019 August 14 – 17, 27th Spine Intervention Society Annual Scientific Conference, NYC, CME 19 hours Category 1.
- 2019 Nov 14 – 16, 18th Annual Pain Medicine Meeting, New Orleans, LA, CME: 23.75 AMA Cat 1 (13.75 hours claimed for MOCA 2.0 Part II CME).

Miscellaneous Conferences:

- 2006 Nov 17 – 18. Current Review of Pain Medicine, NYU, New York City, NY. CEM-1: 10.5 hours.
- 2008 July 12. EMR, ready, set, go, Ohio State Medical Association. CME-1: 4.5 hours
- 2009 July 3, Breast Cancer Update, California Medical Association – CME-1: 1 hours
- 2010 Dec 22 – 24. World Institute of Pain Endorsed Pain Medicine Refresher Course (speaker)

POST GRADUATE TRAINING IN THE UNITED KINGDOME:

- April 1, 1990 – Jan 31, 1991: Senior House Officer, Dept. of Accident and Emergency, Rotherham District General Hospital, Moorgate Road, Rotherham S60 2UD
- Feb 1, 1991 – July 31, 1991: Senior House Officer, Dept. of Orthopedics, Rotherham District General Hospital, Moorgate Road, Rotherham, S60 2UD
- Aug 1, 1991 – July 31, 1992; Senior House Office, Dept. of General Surgery, Rotherham District General Hospital, Moorgate Road, Rotherham, S60 2UD
- Sept 1, 1992 – 25 January 1994; Senior House Officer, Department of General Surgery, Torbay General Hospital, Lawes Bridge, Torquay, TQ2 7AA
- January 27, 1994 – June 15, 1994: Staff Grade General Surgeon, 360 Argyll Street, Dunoon General Hospital, Argyll and Bute Unit, Dunoon, Scotland PA23 7RL, UK.

Post graduate training and private practice in India:

- March 26, 1988 – April 9, 1989: General Surgery Residency, Sher-I-Kashmir Institute of Medical Science, Soura, Srinagar, J&K India
- Nov 1, 1986 – March 15, 1987: General Surgery, Senior House Officer, S.S.K.M Hospital and Institute of Post Graduate Medical Research Institute, 244 A.J.C. Bose Road, Calcutta 700 020, India.
- Aug 16, 1984 – Feb 15, 1986: General Surgery SHO, R. G. Kar Medical College and Hospital, 1. Khudiram Bose Sarani, Calcutta, 700 004, India
- Aug 16, 1983 – Aug 15, 1984: Residential Rotating Housemen, Internal Medicine 8 wks., General Surgery 8 wks., OB&GYN 8 wks., ENT & Ophthalmology 8 wks., Pediatrics 6 wks., Psychiatry 4 wks., and PSM and rural Medicine 6 wks.
- General Practice /Group Practice (Private Practice): Locations: EC 73, Sector 1, Salt Lake City, Calcutta, 700 064, India (2 years and 2 months). 05/01/1989 – 12/31/1989 (7 months), 04/16/1987 – 03/02/1988 (11months) and 02/16/1986 – 10/30/1986 (8 months).

Medical Malpractice Insurance Carrier and History:

- Medical Protective, 5814 Reed Road, Fort Wayne, Indiana 46835, Tel: 800 463 3775. Policy # 671160. Retro from 1/2/2002. $1M/$3M (Claims made coverage). Effective 01/02/2019. Agent's address: Insurance Associates, Jones, Grimes, Long and Snider, PO Box 0911, Middletown, OH 45044-0911. No claims made.
- OHIC Insurance Company, East Broad Street, 13th Floor, Columbus OH 43215. Tel: 6142217777. Policy # 01-9999-6125. Effective from 01/01/2001 to 01/01/2002. $1M/$3M (Occurrence Coverage). Insurance Agent's address: Inmon Insurance Corp, 7216 Shefford Lane, Louisville, KY 40242. No claims made.
- Doctors Insurance Reciprocal, Policy # KDPL 016498-2/00. Effective 8/24/1999 – 8/24/2001. $1/$3 - Claim made coverage. No claims made. Agent: Coverage Option Associates, PO Box 436629, Louisville, KY 40253-6629.
- RI Sound Enterprises Insurance Co, Ltd (RISE). Life Span Risk Services Inc. Address: The CORO building, Suite 170, 167 Point Street, Providence, RI 02903. Tel: 401 444 8273, Fax 401 444 8963. Life span Malpractice Plan. 1999 RISE Policy for Employed Physician in training. New England Medical Center, Inc. LC2-1998/99, Effective from 10/1/1995 to 9/3/1999, Professional Liability Modified Claims made, $2.5/5M. No claims made.

MEMBERSHIP:

- Spine Intervention Society, Active, since 2000
- American Academy of Pain Medicine
- North American Neuromodulation Society
- American Society of Regional Anesthesia
- Massachusetts Medical Society
- American Medical Association